One Cup of Coffee a Day Keeps AF Away? Insights from the DECAF Trial
November 10, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Vyvgart
Synonyms :
efgartigimod alfa-fcab
Class :
Immunoglobulins,Neonatal Fc Receptor Antagonist
Brand Name :
Vyvgart
Synonyms :
efgartigimod alfa-fcab
Class :
Immunoglobulins,Neonatal Fc Receptor Antagonist
Dosage Forms & Strengths:
Injectable solution
400mg/20mL
Patients with anti-acetylcholine receptor antibody positive.
Weight less than 120kg:10mg per kg iv every week for a month.
Weight more than 120 kg:1200mg iv every week for a month.
Dose Adjustments
Renal impairment-Insufficient data are available.
No safety and efficacy have been found
Refer to adult dosing
may decrease the therapeutic effect of Fc Receptor-Binding Agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
it may decrease the effect of nivolumab and reduce blood levels.
tixagevimab and cilgavimab (Investigational)
may decrease the therapeutic effect of Fc Receptor-Binding Agents
may decrease the therapeutic effect of Fc Receptor-Binding agents
May reduce the therapeutic efficacy of Fc Receptor-binding agents
it decreases the efficacy of Fc receptor-binding agents
may decrease the therapeutic effect when combined with fc receptor-binding agents
atoltivimab/maftivimab/odesivimab
By competing for receptor binding, efgartigimod alfa will reduce the level of atoltivimab/maftivimab/odesivimab
it decreases the efficacy of Fc Receptor-Binding Agents
when both drugs are combined, there may be a reduced blood level of cetuximab
when both drugs are combined, there may be a decreased blood levels and effects of daratumumab
may reduce therapeutic effects of Fc receptor-binding agents
when both drugs are combined, there may be a decrease in blood levels and the effects of avelumab
when both drugs are combined, there may be an increased risk of infection
when both drugs are combined, it may diminish the therapeutic effect of Fc Receptor-Binding Agents
it may diminish the therapeutic effect of fc receptor-binding agents
it may reduce the therapeutic efficacy of Fc receptor-binding agents
it may reduce the therapeutic effect of Fc receptor-binding agents
It may reduce the therapeutic efficacy of Fc Receptor-binding agents
may decrease the level of receptor binding competition
it decreases the efficacy of Fc receptor-binding agents
may decrease the effects of receptor binding competition
may decrease the receptor binding competition
it may decrease the therapeutic effect of Fc Receptor-Binding Agents
may decrease the therapeutic effects of Fc receptor binding agents
may decrease the therapeutic effect of Fc receptor binding agents
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect of Fc receptor-binding agents
may decrease the therapeutic activity of Fc receptor-binding agents
may decrease the therapeutic activity of Fc receptor-binding agents
may decrease the therapeutic effect when combined with fc receptor-binding agents
may decrease the therapeutic effect of Fc-binding receptor agents
may decrease the therapeutic effect of Fc Receptor-Binding Agents
may decrease the therapeutic effect of Fc Receptor-Binding Agents
may decrease the therapeutic effect of Fc Receptor-Binding Agents
it decreases the efficacy of Fc Receptor-Binding Agents
may decrease the therapeutic effect of Fc Receptor-Binding Agents
Frequency defined:
Greater than 10%:
Respiratory tract infections
Lymphocytopenia
Nervous disorders such as headaches.
Antibody development
1 to 10% adverse reaction:
Myalgia, urinary tract infections, paresthesia.
Less than 10%:
Hypersensitivity reactions
No contraindications but urinary tract infections have been reported.
Pregnancy consideration: Pregnant patients are not included in the study.No effects were found.
Lactation: The release of the drug into human breast milk is unknown.
Pregnancy category:
Patient information leaflet
Generic Name: efgartigimod alfa (Rx)
Pronounced: [ EF-gar-TIG-i-mod-AL-fa]
Why do we use efgartigimod alfa?
It is used to treat patients with Myasthenia gravis and chronic immunosuppressive therapy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
